Status: Not yet recruiting
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101, compared to placebo, in patients with semantic variant primary progressive aphasia (svPPA), a subtype of frontotemporal dementia (FTD)
Participants needed: 15
Trial details
Phase: Phase 2Age: 55-80Biological sex: AllType: InterventionalSponsor: Hee-Jin KimUpdated: Sep 4, 2025
Eligibility criteria
Participants diagnosed at screening with mild to moderate frontotemporal dementi... [+1]
Participants with other degenerative brain diseases as determined by the investi... [+1]